Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-20
Target enrollment:
Participant gender:
Summary
This study is a multi-regional, randomized, double-blind Phase 3 study to compare the
efficacy and safety of sintilimab plus chemotherapy (sintilimab combination) vs placebo plus
chemotherapy (placebo combination) before surgery and sintilimab vs placebo after surgery in
treatment-naive subjects with resectable Stage IIB (primary tumor > 4 cm) to IIIB (resectable
N2 only) non-small cell lung cancer (NSCLC).